TheStreet’s Action Alerts PLUS Portfolio Manager Jim Cramer said Gilead Sciences is a fine company, but doesn’t have many fans on Wall Street. ‘They’ve developed some really good drugs,’ Cramer said. Back on Tuesday, Gilead announced plans that Kevin Young will rejoin the company as Chief Operating Officer. In the early 2000s, Young was the company’s executive vice president of commercial operations. Gilead’s stock lost 15.5 percent since the start of the year and 24 percent over the past 12 months.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
